Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget: Volume 12, Issue 23.
Oncotarget’s Volume 12, Issue #23
Cover (Research Paper): Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States – retrospective real world data
Origin: Mississippi, California, Indiana, New Jersey, Texas, Maryland, United States; Beijing, China
Institutions: University of Mississippi Medical Center, Roche Information Solutions, Roche Diagnostics Corporation, Genesis Research, Houston Methodist Hospital
Quote: “This study assessed the prevalence of anaplastic lymphoma kinase (ALK) rearrangements in US oncology practices.”
News: Excitement for our future
Origin: Washington, DC, United States
Institution: Georgetown University Medical Center
Quote: “News on: Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients by Leaf et al. Oncotarget. 2021; 12:1992–2005. https://doi.org/10.18632/oncotarget.28082. [PubMed]”
Editorial Paper: Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)
Origin: Pennsylvania, United States
Institution: University of Pittsburgh Medical Center
Quote: “Among all immune checkpoints, the PD-L1/PD-1 axis has been confirmed as therapeutic target in many malignancies from clinical trials of immune checkpoint blockade (ICB) alone or in combination with other therapeutics. The recent IMbrave150 clinic trial combining atezolizumab with bevacizumab shows encouraging antitumor activity in patients with unresectable hepatocellular carcinoma (HCC) .”
Editorial Paper: Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
Origin: Florida, United States
Institution: Brooke Army Medical Center
Quote: “Preclinical data allude to a synergistic effect of HER2-targeted therapy, with or without concomitant cytotoxic chemotherapy, when combined with either checkpoint inhibitors, or cancer vaccine immunotherapy [3–6].”
Click here to read Oncotarget’s Volume 12, Issue #23.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact firstname.lastname@example.org.